Submitted by Setor de Tratamento da Informa??o - BC/PUCRS (tede2@pucrs.br) on 2015-07-07T13:12:21Z No. of bitstreams: 1 471733 - Texto Completo.pdf: 3943882 bytes, checksum: 020e81f1866b17fd0827985be752adfe (MD5) / Made available in DSpace on 2015-07-07T13:12:21Z (GMT). No. of bitstreams: 1 471733 - Texto Completo.pdf: 3943882 bytes, checksum: 020e81f1866b17fd0827985be752adfe (MD5) Previous issue date: 2015-03-11 / Context : prevalence of obesity and metabolic syndrome (MetS) are increasing worldwide, behavioral modification therapy (diet and regular physical exercise) and pharmacotherapy present little success and low adherence to the treatment of these pathologies. Bariatric surgery for bypass technique, however, has shown promising and effective results in both, reducing weight and associated comorbidities of obese patients II and III. Objective: to evaluate the impact of gastric bypass in MetS components and in the use of associated drugs.Method : historical cohort, follow-up for six months, analyzing a sample composed by 273 obese people [236 (86.4%) female and 37 (13.6%) males] grade II and grade III, aged ? 20 years, with or without MetS who underwent bariatric surgery by Roux-en-Y bypass technique between January 2007 and March 2014. All patients were followed for a period of six months after surgery and evaluated at 60, 120 and 180 days after surgery. The socio-demographic, anthropometric, biochemical, clinical and medication use data were collected from medical records of patients.Results : the results show significant statistical differences in post-operative period, either 60, 120 or 180 days, concerning the following variables: weight (p <0.001), BMI (p <0.001), CA (p <0.001), SAP (p <0.001), DBP (p <0.001), glucose (P = 0.005 post 60 and p <0.001 post 120 and 180 days), triglycerides (p <0.001). In relation to HDL levels did not change was observed (p> 0.05). Concerning the use of drugs, were also observed significant statistical reductions in the use of antihypertensive drugs (p <0.001), hypoglycaemics (p <0.001) and lipid-lowering (p <0.001).Conclusions : that patients who underwent Roux-en-Y gastric bypass had a weight loss and an improvement in MetS components (except HDL) and in the use of drugs associated with obesity and MetS. / Introdu??o : embora a preval?ncia da obesidade e da s?ndrome metab?lica (SM) esteja aumentando mundialmente, terapias de modifica??o comportamental (dieta e pr?tica de exerc?cio f?sico regular) e a farmacoterapia apresentam pouco sucesso e baixa ades?o. A cirurgia bari?trica pela t?cnica de bypass (Y-de-Roux) tem mostrado resultados promissores e eficazes tanto na redu??o do peso quanto nas comorbidades associadas de pacientes obesos II e III. Objetivo: avaliar o impacto do bypass g?strico (Y-de-Roux) nos componentes da SM e no uso de medicamentos associados.M?todos : coorte hist?rica, follow-up de seis meses. A amostra foi composta por 273 indiv?duos obesos [236 (86,4%) do sexo feminino e 37 (13,6%) do sexo masculino] grau II e grau III, com idade ? 20 anos, portadores ou n?o de SM e que realizaram cirurgia bari?trica pela t?cnica de bypass (Y- de- Roux) entre janeiro de 2007 e mar?o de 2014. Todos os pacientes foram acompanhados por um per?odo de seis meses ap?s o procedimento cir?rgico, com avalia??o em 60, 120 e 180 dias ap?s a cirurgia. Os dados s?cio-demogr?ficos, antropom?tricos, bioqu?micos, cl?nicos e de uso de medicamentos foram coletados dos prontu?rios m?dicos dos pacientes.Resultados : foram verificadas diferen?as estatisticamente significativas no p?s-cir?rgico, ap?s 60, 120 e 180 dias, no peso (p<0,001), no IMC (p<0,001), na CA (p<0,001), na PAS (p<0,001), na PAD (p<0,001), na glicemia (p=0,005 no p?s 60 e p<0,001 no p?s 120 e 180 dias) e nos triglicer?deos (p< 0,001). Em rela??o aos n?veis de HDL, n?o se observou altera??o (p>0,05). Quanto ao uso de medicamentos, tamb?m foram observadas redu??es estatisticamente significativas no uso de anti-hipertensivos (p<0,001), hipoglicemiantes (p<0,001) e hipolipemiantes (p<0,001).Conclus?o : pacientes submetidos ao bypass g?strico (Y-de-Roux) apresentaram perda de peso e melhora significativas nos componentes da SM (exceto no HDL) e no uso de medicamentos associados ? obesidade e ? SM.